659 related articles for article (PubMed ID: 8395305)
21. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.
Martin BR; Compton DR; Thomas BF; Prescott WR; Little PJ; Razdan RK; Johnson MR; Melvin LS; Mechoulam R; Ward SJ
Pharmacol Biochem Behav; 1991 Nov; 40(3):471-8. PubMed ID: 1666911
[TBL] [Abstract][Full Text] [Related]
22. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological evaluation of halogenated delta 8-THC analogs.
Charalambous A; Lin S; Marciniak G; Banijamali A; Friend FL; Compton DR; Martin BR; Makriyannis A
Pharmacol Biochem Behav; 1991 Nov; 40(3):509-12. PubMed ID: 1666915
[TBL] [Abstract][Full Text] [Related]
24. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.
Breivogel CS; Scates SM; Beletskaya IO; Lowery OB; Aceto MD; Martin BR
Eur J Pharmacol; 2003 Jan; 459(2-3):139-50. PubMed ID: 12524139
[TBL] [Abstract][Full Text] [Related]
25. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.
Sim LJ; Hampson RE; Deadwyler SA; Childers SR
J Neurosci; 1996 Dec; 16(24):8057-66. PubMed ID: 8987831
[TBL] [Abstract][Full Text] [Related]
26. Competitive inhibition of delta8-tetrahydrocannabinol and its active metabolites for cannabinoid receptor binding.
Yamamoto I; Kimura T; Kamei A; Yoshida H; Watanabe K; Ho IK; Yoshimura H
Biol Pharm Bull; 1998 Apr; 21(4):408-10. PubMed ID: 9586583
[TBL] [Abstract][Full Text] [Related]
27. Determination and characterization of a cannabinoid receptor in rat brain.
Devane WA; Dysarz FA; Johnson MR; Melvin LS; Howlett AC
Mol Pharmacol; 1988 Nov; 34(5):605-13. PubMed ID: 2848184
[TBL] [Abstract][Full Text] [Related]
28. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats.
Lichtman AH; Dimen KR; Martin BR
Psychopharmacology (Berl); 1995 Jun; 119(3):282-90. PubMed ID: 7675962
[TBL] [Abstract][Full Text] [Related]
29. Differential modulations of striatal tyrosine hydroxylase and dopamine metabolism by cannabinoid agonists as evidence for functional selectivity in vivo.
Bosier B; Muccioli GG; Mertens B; Sarre S; Michotte Y; Lambert DM; Hermans E
Neuropharmacology; 2012 Jun; 62(7):2328-36. PubMed ID: 22365976
[TBL] [Abstract][Full Text] [Related]
30. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain.
Breivogel CS; Childers SR; Deadwyler SA; Hampson RE; Vogt LJ; Sim-Selley LJ
J Neurochem; 1999 Dec; 73(6):2447-59. PubMed ID: 10582605
[TBL] [Abstract][Full Text] [Related]
31. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
32. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain.
Abood ME; Sauss C; Fan F; Tilton CL; Martin BR
Pharmacol Biochem Behav; 1993 Nov; 46(3):575-9. PubMed ID: 8278434
[TBL] [Abstract][Full Text] [Related]
33. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
34. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development.
De Vry J; Jentzsch KR; Kuhl E; Eckel G
Behav Pharmacol; 2004 Feb; 15(1):1-12. PubMed ID: 15075621
[TBL] [Abstract][Full Text] [Related]
35. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland.
González S; Manzanares J; Berrendero F; Wenger T; Corchero J; Bisogno T; Romero J; Fuentes JA; Di Marzo V; Ramos JA; Fernández-Ruiz J
Neuroendocrinology; 1999 Aug; 70(2):137-45. PubMed ID: 10461028
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid ligand-receptor signaling in the mouse uterus.
Das SK; Paria BC; Chakraborty I; Dey SK
Proc Natl Acad Sci U S A; 1995 May; 92(10):4332-6. PubMed ID: 7753807
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of a novel synthetic cannabinoid CP 55,940 binder in rat brain cytosol.
Qureshi J; Saady M; Cardounel A; Kalimi M
Mol Cell Biochem; 1998 Apr; 181(1-2):21-7. PubMed ID: 9562238
[TBL] [Abstract][Full Text] [Related]
38. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation.
Kaminski NE; Abood ME; Kessler FK; Martin BR; Schatz AR
Mol Pharmacol; 1992 Nov; 42(5):736-42. PubMed ID: 1279376
[TBL] [Abstract][Full Text] [Related]
39. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.
Wiley JL; Barrett RL; Lowe J; Balster RL; Martin BR
Neuropharmacology; 1995 Jun; 34(6):669-76. PubMed ID: 7566504
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans.
Skosnik PD; Hajós M; Cortes-Briones JA; Edwards CR; Pittman BP; Hoffmann WE; Sewell AR; D'Souza DC; Ranganathan M
Neuropharmacology; 2018 Jun; 135():412-423. PubMed ID: 29604295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
